Corcept Therapeutics Inc (CORT) Stock Price & Analysis
Corcept Therapeutics Inc (CORT) fell 1.05% to USD 111.62 as of September 8, 2026 at 05:00 UTC, according to Nexqual real-time market data.
CORT last closed at USD 111.62; the session ranged USD 109.26–112.13 on volume of 604,556 shares. Market capitalization is —, with a 52-week range of USD 28.66–126.38 (NCM). Source: Nexqual, September 8, 2026 at 05:00 UTC.
Key Statistics (as of September 8, 2026 at 05:00 UTC)
| Price | USD 111.62 |
|---|---|
| Change | ▼ 1.05% (down) |
| Previous Close | USD 111.62 |
| Open | USD 111.62 |
| Day Range | USD 109.26 – 112.13 |
| 52-Week Range | USD 28.66 – 126.38 |
| Volume | 604,556 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CORT)
Nexqual's technical model rates CORT "BUY" based on 4 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:00 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.83 (neutral) |
| vs SMA50 | Above (USD 104.08) |
| MACD | 2.46 (positive) |
From Corcept Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism.
- The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy ("REMS"), to assure the safe use of the product.
- We are developing our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
- We are testing the potential of our proprietary, selective cortisol modulator, nenocorilant to treat cancer by reducing cortisol-activated immune suppression and thereby help the patient's immune system reduce or eradicate tumors while they receive immunotherapy.
Partnerships
- In June 2025, we notified Optime that it would cease to be our exclusive specialty pharmacy and in October 2025, we delivered a notice of termination of our agreement with them, effective January 8, 2026.
- In collaboration with the Paris-based academic research cooperative ARCAGY-GINECO, we will initiate, in the first quarter of 2026, a Phase 2 trial, STELLA, in 50 patients with cervical cancer, who have received one or two prior lines of therapy.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | USD 72.72 | ▲ 1.1% |
| SUPN | Supernus Pharmaceuticals, Inc. | USD 43.53 | ▼ 1.14% |
| HALO | Halozyme Therapeutics, Inc. | USD 110.19 | ▲ 0.48% |
| VNDA | Vanda Pharmaceuticals Inc. | USD 5.43 | ▼ 1.81% |
| INVA | Innoviva, Inc. | USD 21.33 | ▼ 0.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:00 UTC. This page is informational and not investment advice.